Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.

The US Food and Drug Administration (FDA) Expanded Access (EA) Program, which allows for compassionate uses of unapproved therapeutics and diagnostics outside of clinical trials, has gained significant traction during the Coronavirus 2019 (COVID-19) pandemic. While development of vaccines has been t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drug Discov Today
Asıl Yazarlar: Rizk, John G., Forthal, Donald N., Kalantar-Zadeh, Kamyar, Mehra, Mandeep R., Lavie, Carl J., Rizk, Youssef, Pfeiffer, JoAnn P., Lewin, John C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier Ltd. 2021
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7694556/
https://ncbi.nlm.nih.gov/pubmed/33253920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2020.11.025
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller